Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesSafety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding
Inflammatory Bowel Disease, 11/04/09
Gisbert JP et al. – Certolizumab differs from infliximab and adalimumab in that it is a Fab fragment of an antitumor necrosis factor alpha monoclonal antibody, and therefore it may not be necessary to stop certolizumab in the third trimester. The use of infliximab is probably compatible with breast–feeding.
Related Articles
Novel Diagnostic and Prognostic Modalities in Inflammatory Bowel Disease
Gastroenterology Clinics of North America, 11/17/09
Relevance Score: 83%
Pregnancy and Inflammatory Bowel Disease
Gastroenterology Clinics of North America, 11/17/09
Relevance Score: 83%
Pathogenesis of inflammatory bowel disease (IBD)
The Internet Journal of Gastroenterology, 11/13/09
Relevance Score: 83%
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
The Lancet, 11/09/09
Relevance Score: 83%
Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history
Expert Review of Gastroenterology & Hepatology, 10/13/09
Relevance Score: 83%
Today in Gastroenterology...keeping you current
Receive free subspecialty "5-minute updates" via email
Universal Mass Vaccination Against Rotavirus Gastroenteritis: Impact on Hospitalization Rates in Austrian Children
The Pediatric Infectious Disease Journal, 12/04/09
Rectal Fecal Impaction Treatment in Childhood Constipation: Enemas Versus High Doses Oral PEG
Pediatrics, 12/04/09
Blood in the stool raises concerns
The Clinical Advisor, 12/04/09
Sponsor
Article Search
Sponsor